Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
By reducing joint inflammation, IRAP therapy promotes long-term joint health
GHK-Cus expansive published evidence base simplifies literature justification in protocol documentation, grant applications, and institutional review submissions
Current Phase 3 trials (expected to report results in 2027) are exploring doses ranging from 4mg to 12mg weekly, with some protocols testing up to 16mg
AOD-9604 Growth Hormone Research Growth Hormone Research reference compound Studied as a growth hormone research reference compound
10.1016/0165-1218(84)90081-8 Mutat
US$ 29.63
US$ 25.67
US$ 28.68
US$ 22.24
US$ 24.42
